Obviously, this phenomenon is associated with therapeutic implications, since the main breakthrough in cancer immunotherapy is treatment based on breach of the PD-L1/PD-1 axis between cancer cells and cytotoxic T cells. The gene discussed is CD274; the disease is cancer.